

Product Specification Sheet

**ODN 2216 -Type A human TLR9 agonist-Controls and Conjugates (antigen grade)**

□ <b>Cat. # ODN2216-1</b>	ODN 2216- Type A human TLR9 Agonist, antigen grade	<b>Size: 1 mg</b>
□ <b>Cat. # ODN2216-5</b>	ODN 2216- Type A human TLR9 Agonist, antigen grade	<b>Size: 5 mg</b>
□ <b>Cat. # ODN2216-1NC</b>	ODN 2216- Type A human TLR9 Agonist (Negative Control), antigen grade	<b>Size: 1 mg</b>
□ <b>Cat. # ODN2216-5NC</b>	ODN 2216- Type A human TLR9 Agonist (Negative Control), antigen grade	<b>Size: 5 mg</b>
□ <b>Cat. # ODN2216-F</b>	ODN 2216- Type A human TLR9 Agonist <b>FITC</b> Conjugate, antigen grade	<b>Size: 50 ug</b>
□ <b>Cat. # ODN2216-B</b>	ODN 2216- Type A human TLR9 Agonist <b>Biotin</b> Conjugate, antigen grade	<b>Size: 50 ug</b>

CpG oligodeoxynucleotides (or CpG ODN) are short single-stranded synthetic DNA molecules that contain an unmethylated CG (Cytosine-guanine) di nucleotide in a specific base sequence (CpG motifs). The p refer to the phosphodiester backbone. These CpG motifs are not seen in eukaryotic DNA are considered pathogen-associated molecular patterns (PAMPs). The CpG PAMP is recognized by (TLR9). 3 types of, stimulatory ODNs have been identified based upon immunostimulatory activities.

Class A stimulate the production of large amounts of Type I interferons, induce the maturation of pDCs. They are also strong activators of NK cells through indirect cytokine signaling.

Class B ODN are strong stimulators of bovine/porcine B cell and monocyte maturation. They also stimulate the maturation of pDC but to a lesser extent than Class A ODN and very small amounts of IFN $\alpha$ .

Class C ODN combine features of both types A and B. They contain a complete phosphorothioate backbone and a CpG-containing palindromic motif. They induce strong IFN- $\alpha$  production from DC and B cell stimulation.

**ODN 2216** is a TLR9. Type A human specific TLR9 agonist. In studies in leukemia patients ODN 2216 induced higher concentrations of IFN- $\gamma$ , IL-12 in supernatant. The percentages of Th1 and Tc1 cells increased significantly after culture with CpG ODN 2216 as compared with control group. The killing effect of peripheral blood mononuclear cells (PBMCs) on K562 cells (a tumor cell line) was significantly different between the stimulated group and control group. It was concluded that CpG ODNs 2216 can induce strong Th1-like immune activation, with the secretion of type-I cytokine and activation of strong CD8(+) T-cell responses. PBMCs activated by CpG ODNs can more strongly kill k562 cells in vitro.

**Cat. #:ODN2216-1 & ODN2216-5**

<b>Sequence</b>	5'ggGGGACGATCGTCgggggg-3'(20 mer)
<b>Mol. Wt</b>	6644
<b>Purity</b>	≥95%
<b>Form and storage</b>	Powder. Store at -20C up to 1 year.
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**Notes:**

- 1) Bases in capital are phosphodiester and those in lower case are phosphorothioate. Palindromic sequences are underlined.
- 2) Negative control Contains GpC nucleotides instead of CpG.

**Cat. #:ODN2216-1NC & Cat. #:ODN2216-5NC (negative control)**

<b>Sequence</b>	5'ggGGGAGCATGCTGgggggg-3' (20 mer)
<b>Mol. Wt.</b>	6644
<b>Purity</b>	≥95%
<b>Form and Storage</b>	Powder. Store at -20C upto 1 year.
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**Cat. #:ODN2216-F, FITC Conjugate**

<b>Sequence</b>	5'ggGGGACGATCGTCgggggg-FITC'(20 mer)
<b>Purity</b>	≥95%
<b>Form and Storage</b>	Powder. Store at -20C upto 1 year.
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**Cat. #:ODN2216-B, Biotin Conjugate**

<b>Sequence</b>	5'ggGGGACGATCGTCgggggg-biotin '(20 mer)
<b>Purity</b>	≥95%
<b>Form and Storage</b>	Powder. Store at -20C upto 1 year.
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**General references:** Krieg,A.M(1995). Nature, 374(6522):546-9. Ballaz ZK(2001) 167(9). Bauer, (2001).PNAS.98(16):9237-42. Zhongguo Shi (2009) 17(4):874-8.

*\*for in vitro research only\**

**Related Items**

Catalog# ProdDescription  
 ODN006-1 ODNBW006 Type B CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' end  
 ODN1668-1 ODN 1668-Type B murine TLR9 Agonist-Antigen grade  
 ODN1668-1NCODN 1668- Type B murine TLR9 Agonist (Negative Control), antigen grade  
 ODN1826-1 ODN 1826- Type B murine TLR9 Agonist-antigen grade  
 ODN2006-1 ODN 2006 -Type B-human TLR9 agonist-antigen grade  
 ODN2007-1 ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade  
 ODN2216-1 ODN 2216-Type A human TLR9 Agonist.-antigen grade  
 ODN2395-5 ODN 2395-Type C human/murine TLR9 agonist-antigen grade  
 ODN4084F-1ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade  
 ODN4084F-5ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade  
 ODNTT-1NC ODN TTAGGG-Class G Human-TLR 9 Antagonist, antigen grade  
 SIODN-1 Inhibitory iODN- class I/II hybrid, may also affect TLR7 and TLR8 signaling.

ODN 2216

rev140220N